Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Biontech
Research and Development in Biotechnology (except Nanobiotechnology)Germany
Last verified 10 months agobiontech.de
BioNTech SE, headquartered in Mainz, Germany, is a leading player in the Research and Development sector of biotechnology, excluding nanobiotechnology. Founded in 2008, the company has made significant strides in mRNA technology, particularly in the development of innovative therapies and vaccines for infectious diseases and cancer.
With a strong focus on personalised medicine, BioNTech's core products include its groundbreaking mRNA-based vaccines, which gained global recognition during the COVID-19 pandemic. The company has established itself as a pioneer in the biotechnology field, achieving notable milestones such as the rapid development of its COVID-19 vaccine in collaboration with Pfizer.
BioNTech's commitment to advancing healthcare solutions positions it as a formidable entity in the biotechnology landscape, with a robust pipeline of therapeutic candidates aimed at addressing unmet medical needs.
48
DitchCarbon score
+22 vs industry average
Biontech’s score of 48 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Biontech?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Low
Research and Development in Biotechnology (except Nanobiotechnology) has below-average carbon intensity
Industry performance
0.198
20182025
The Research and Development in Biotechnology (except Nanobiotechnology) industry has reduced its overall emissions by 19% since 2018
Emissions trajectory 2020 – 2028
202020212022202320242025202620272028
Reported emissions
Scope 1
•••kg CO₂e
Scope 2
•••kg CO₂e
Scope 3
•••kg CO₂e
Total reported
•••kg CO₂e
Scope 3 accounts for ••• of total emissions.
Biontech's reported carbon emissions
BioNTech, a German-based company in Research and Development in Biotechnology, reported total carbon emissions of approximately 711.6 million kg CO2e in 2025. This includes Scope 1 emissions of 2.2 million kg CO2e, and Scope 3 emissions of about 703.6 million kg CO2e. Scope 2 emissions, which include purchased heat, steam, cooling, and electricity, were approximately 5.8 million kg CO2e (market-based).
In 2024, BioNTech's total emissions were approximately 892.9 million kg CO2e, with Scope 1 at 2.4 million kg CO2e, Scope 2 at 4.0 million kg CO2e (market-based), and Scope 3 at about 886.4 million kg CO2e. For 2023, total emissions were about 534.2 million kg CO2e, comprising Scope 1 emissions of 1.3 million kg CO2e, Scope 2 emissions of 3.3 million kg CO2e (market-based), and Scope 3 emissions of approximately 529.5 million kg CO2e.
Looking further back, in 2022, the company's total emissions were approximately 1.12 billion kg CO2e, with Scope 1 emissions of 0.87 million kg CO2e and Scope 3 emissions of around 1.12 billion kg CO2e. Scope 2 market-based emissions were approximately 3.16 million kg CO2e. In 2021, BioNTech's Scope 1 emissions were approximately 0.89 million kg CO2e and Scope 2 market-based emissions were about 2.34 million kg CO2e. For 2020, Scope 1 emissions were around 0.70 million kg CO2e and Scope 2 market-based emissions were about 3.85 million kg CO2e. In 2019, Scope 1 emissions were about 0.61 million kg CO2e and Scope 2 market-based emissions were approximately 2.75 million kg CO2e. Note that Scope 3 emissions were not reported for 2019, 2020, and 2021.
BioNTech is committed to reducing its climate impact. The company has set near-term Science Based Targets initiative (SBTi) aligned targets to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by 2030, using 2021 as the base year. Additionally, BioNTech aims for 72% of its suppliers, by emissions covering purchased goods and services, capital goods, and upstream transportation and distribution, to have science-based targets by 2027. These commitments have been confirmed by the SBTi.
Assessing Biontech as a supplier or portfolio company?
- See verified emissions data for over 2 million organizations
- View emissions forecasts for Biontech and the organizations you buy from or invest in
- Get PCAF data quality (DQ) scores, including for private organizations
Biontech’s Climate Goals (2030 & 2050)
2 goals2030
42% reduction in Scope 1
BioNTech commits to reduce absolute scope 1 and 2 GHG emissions 42% by 2030 from a 2021 base year. BioNTech commits that 72% of its supplier…
Behind target42%
2030
42% reduction in Scope 2
BioNTech commits to reduce absolute scope 1 and 2 GHG emissions 42% by 2030 from a 2021 base year. BioNTech commits that 72% of its supplier…
Behind target42%
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
2030 targetSee details
Active
Carbon Disclosure Project
See details
Not active
The Climate Pledge
See details
Not active
UN Global Compact Climate Champions initiative
See details
Not active
RE 100
See details
Not active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
Biontech10 months ago
48
Need this data for financed emissions?
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Frequently asked questions
Common questions about Biontech’s sustainability data and climate commitments
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more